Drug Price Trends for BREYNA

Average Pharmacy Cost for BREYNA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
BREYNA 160-4.5 MCG INHALER	00378-7503-32	23.19761	GM	2024-12-18
BREYNA 80-4.5 MCG INHALER	00378-7502-32	20.24539	GM	2024-12-18
BREYNA 160-4.5 MCG INHALER	00378-7503-32	23.30965	GM	2024-11-20
BREYNA 80-4.5 MCG INHALER	00378-7502-32	20.58045	GM	2024-11-20
BREYNA 160-4.5 MCG INHALER	00378-7503-32	23.30068	GM	2024-10-23
BREYNA 80-4.5 MCG INHALER	00378-7502-32	20.07126	GM	2024-10-23
BREYNA 160-4.5 MCG INHALER	00378-7503-32	23.36849	GM	2024-09-18

Market Analysis and Price Projections for Breyna

Introduction to Breyna

Breyna, a generic version of AstraZeneca's blockbuster drug Symbicort, has been launched by Viatris and Kindeva Drug Delivery. This drug-device combination, a metered-dose inhaler, is approved for the treatment of asthma in patients aged six and above, as well as for the maintenance treatment of chronic obstructive pulmonary disease (COPD) patients[1][4].

Market Impact of Breyna's Launch

The launch of Breyna marks a significant milestone in the respiratory and immunology segment, particularly for the treatment of asthma and COPD. After years of legal hurdles, including patent litigation that began in 2018, Breyna has finally entered the market, poised to capture a portion of Symbicort's market share.

Impact on Symbicort Sales

Symbicort, which has enjoyed market exclusivity since its launch in 2006, has seen its sales decline from a peak of $3.8 billion in 2014 to $2.5 billion in 2022. The introduction of Breyna is expected to further reduce Symbicort's sales, as it offers a more affordable alternative. This decline is anticipated to prompt AstraZeneca to focus on other high-growth products within its Respiratory & Immunology segment, such as Fasenra[1].

Growth Driver for Viatris

Breyna is expected to be a crucial growth driver for Viatris. The company has reaffirmed its financial guidance for 2023, anticipating total sales to fall within the range of $15.5 billion to $16.0 billion, with $500 million attributed to new product sales, including Breyna. Viatris is also set to benefit from a 180-day exclusivity period as the first manufacturer to file an abbreviated new drug application for the Symbicort generic[1].

Pricing and Affordability

To enhance accessibility and affordability, Viatris has introduced a co-pay program for Breyna. This program offers eligible commercially-insured patients a reduced out-of-pocket expense, with prescriptions available for as little as $20 per 30-day supply, or up to $360 per year with 12 refills annually[4].

Market Prices

The cost of Breyna varies depending on the dosage strength and pharmacy. For example, the 160 mcg/4.5 mcg/inh inhalation aerosol is priced around $388 for a supply of 10.3 grams, while the 80 mcg/4.5 mcg/inh version is priced from $340.52 for the same quantity[2].

Competitive Landscape

Generic Competition

The success of Breyna is likely to attract other generic entrants into the market. Companies like Cipla are expected to follow suit, increasing competition and potentially driving prices down further. This competitive environment will continue to shape the market dynamics for asthma and COPD treatments[1].

Market Share

Breyna's entry into the market is well-timed, given the rising pricing pressures in key markets such as the US, Mainland China, and the EU. By offering a generic alternative, Viatris and Kindeva aim to capture a significant share of the market previously dominated by Symbicort[1].

Market Projections

Sales Projections

Viatris expects significant sales growth from Breyna, particularly during the 180-day exclusivity period. However, as more generic versions of Symbicort enter the market, the sales growth may stabilize. The company's financial guidance includes $500 million in new product sales, which Breyna is expected to contribute substantially to[1].

Market Size and Growth

The global drug delivery systems market, which includes inhalation aerosols like Breyna, is projected to grow from $46.23 billion in 2024 to $63.38 billion by 2032, exhibiting a CAGR of 4.0%. This growth is driven by factors such as new product launches, increased R&D, and the rising prevalence of chronic diseases like asthma and COPD[3].

Key Takeaways

• Market Entry: Breyna, the first generic version of Symbicort, has been launched by Viatris and Kindeva, marking a significant shift in the treatment landscape for asthma and COPD.
• Pricing and Affordability: Breyna is priced competitively, with a co-pay program to reduce out-of-pocket expenses for eligible patients.
• Sales Impact: The launch of Breyna is expected to negatively impact Symbicort's sales, prompting AstraZeneca to focus on other growth areas.
• Growth Driver: Breyna is anticipated to be a key growth driver for Viatris, contributing to the company's new product sales.
• Competitive Landscape: The success of Breyna will likely attract other generic entrants, increasing competition in the market.

FAQs

Q: What is Breyna, and how does it differ from Symbicort? A: Breyna is the first generic version of AstraZeneca's Symbicort, a drug-device combination used for treating asthma and COPD. It offers the same active ingredients (budesonide and formoterol fumarate dihydrate) but at a lower cost.

Q: How will the launch of Breyna affect Symbicort's sales? A: The launch of Breyna is expected to negatively impact Symbicort's sales, as it provides a more affordable alternative, leading to a decline in Symbicort's market share.

Q: What pricing strategies has Viatris implemented for Breyna? A: Viatris has introduced a co-pay program to reduce out-of-pocket expenses for eligible commercially-insured patients, making Breyna more affordable.

Q: Will other generic versions of Symbicort enter the market? A: Yes, the success of Breyna is likely to attract other generic entrants, increasing competition and potentially driving prices down further.

Q: How does Breyna fit into the broader market for drug delivery systems? A: Breyna is part of the growing global drug delivery systems market, which is projected to grow from $46.23 billion in 2024 to $63.38 billion by 2032, driven by new product launches and increased R&D.

Sources

1. Fitch Solutions: "Viatris And Kindeva's Breyna Launch Provides First Generic Competition To AstraZeneca's Blockbuster Symbicort"[1].
2. Drugs.com: "Breyna Prices, Coupons, Copay Cards & Patient Assistance"[2].
3. Fortune Business Insights: "Drug Delivery Systems Market Size, Share | Global Report [2032]"[3].
4. Viatris Newsroom: "Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol"[4].